ArticleGynecologic oncology reports2023
Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature.
Article in Gynecologic oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Metachronous Double Primary Malignancies of Invasive Ductal Carcinoma of the Breast and Primary Ovarian Angiosarcoma.Iranian journal of pathology · 2026Article
- Upfront Cytoreductive Surgery as a Bridge to Systemic Therapy for Recurrent Peritoneal Dissemination of Ovarian Angiosarcoma: A Pediatric Case Report.Surgical case reports · 2026Article
- Atypical Pelvic Tumors in Children.Cancers · 2025Article
- Ovarian Angiosarcoma With Intractable Intraperitoneal Hemorrhage: A Case Report and Review of the Literature.Cureus · 2025Article
- Primary Ovarian Angiosarcoma: Diagnostic Challenges and Conundrums.Discoveries (Craiova, Romania)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
•Primary angiosarcoma of the ovary historically has no standard treatment due to its rarity, and outcomes have been variable.•Olaparib may represent a viable treatment option for primary angiosarcoma of the ovary with a somatic BRCA mutation.•Next-generation sequencing may play an important component in treatment of very rare cancers to guide new or uncommon therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.